Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company's products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company's product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company's products consist of instruments, consumables and systems that are made up of various individual products.
Industry, Sector and Symbol:
- Sector: Computer and Technology
- Industry: Medical Instruments & Supplies
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:HBIO
- CUSIP: 41690610
- Web: www.harvardbioscience.com
Capitalization:- Market Cap: $79.62 million
- Outstanding Shares: 34,618,000
Average Prices:- 50 Day Moving Avg: $2.42
- 200 Day Moving Avg: $2.67
- 52 Week Range: $2.25 - $3.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 12.11
- P/E Growth: 1.57
Sales & Book Value:- Annual Revenue: $101.71 million
- Price / Sales: 0.78
- Book Value: $2.10 per share
- Price / Book: 1.10
Profitability:- EBIDTA: $2.53 million
- Net Margins: -18.90%
- Return on Equity: 3.73%
- Return on Assets: 2.48%
Debt:- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 3.20%
- Quick Ratio: 1.73%
Misc:- Average Volume: 90,889 shs.
- Beta: 1.11
- Short Ratio: 3.54
Frequently Asked Questions for Harvard Bioscience (NASDAQ:HBIO)
What is Harvard Bioscience's stock symbol?
Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."
How were Harvard Bioscience's earnings last quarter?
Harvard Bioscience, Inc. (NASDAQ:HBIO) released its earnings results on Thursday, March, 9th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.04 by $0.03. The business had revenue of $26.42 million for the quarter, compared to the consensus estimate of $26.90 million. Harvard Bioscience had a negative net margin of 18.90% and a positive return on equity of 3.73%. View Harvard Bioscience's Earnings History.
Where is Harvard Bioscience's stock going? Where will Harvard Bioscience's stock price be in 2017?
2 analysts have issued 1 year target prices for Harvard Bioscience's stock. Their predictions range from $5.50 to $6.00. On average, they anticipate Harvard Bioscience's stock price to reach $5.75 in the next twelve months. View Analyst Ratings for Harvard Bioscience.
Who are some of Harvard Bioscience's key competitors?
Some companies that are related to Harvard Bioscience include Sientra (SIEN), Invuity (IVTY), Lakeland Industries (LAKE), BIOLASE (BIOL), Transenterix (TRXC), Presbia PLC (LENS), Tandem Diabetes Care (TNDM), Strata Skin Sciences (SSKN), Neurometrix (NURO), Dextera Surgical (DXTR), Alphatec Holdings (ATEC), Derma Sciences (DSCI), HeartWare International (HTWR), Mindray Medical International Ltd (MR), Thoratec (THOR), Trivascular Technologies (TRIV) and Unilife Corp (UNIS).
Who owns Harvard Bioscience stock?
Harvard Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional investors include Heartland Advisors Inc. (6.07%), Dimensional Fund Advisors LP (4.72%), Royce & Associates LP (4.50%), Vanguard Group Inc. (4.38%), Granahan Investment Management Inc. MA (2.94%) and Jupiter Asset Management Ltd. (2.26%). Company insiders that own Harvard Bioscience stock include David Green, Earl R Lewis, George Uveges, Jeffrey Duchemin, John F Kennedy and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.
Who sold Harvard Bioscience stock? Who is selling Harvard Bioscience stock?
Harvard Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Jupiter Asset Management Ltd., First Manhattan Co., ClariVest Asset Management LLC, ICM Asset Management Inc. WA, Segall Bryant & Hamill LLC, Acadian Asset Management LLC and United Services Automobile Association. Company insiders that have sold Harvard Bioscience stock in the last year include David Green and Earl R Lewis. View Insider Buying and Selling for Harvard Bioscience.
Who bought Harvard Bioscience stock? Who is buying Harvard Bioscience stock?
Harvard Bioscience's stock was bought by a variety of institutional investors in the last quarter, including Heartland Advisors Inc., Essex Investment Management Co. LLC, Royce & Associates LP, Foundry Partners LLC, Renaissance Technologies LLC, Vanguard Group Inc., Dimensional Fund Advisors LP and Algert Global LLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Earl R Lewis, George Uveges, Jeffrey Duchemin, John F Kennedy and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.
How do I buy Harvard Bioscience stock?
Shares of Harvard Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Harvard Bioscience stock cost?
One share of Harvard Bioscience stock can currently be purchased for approximately $2.30.
Consensus Ratings for Harvard Bioscience (NASDAQ:HBIO) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $5.75 (150.00% upside) |
Analysts' Ratings History for Harvard Bioscience (NASDAQ:HBIO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/21/2016 | Benchmark Co. | Set Price Target | Buy | $6.00 | N/A |  |
| 11/17/2016 | Singular Research | Initiated Coverage | Buy | $5.50 | N/A | |
(Data available from 5/25/2015 forward)
Earnings History for Harvard Bioscience (NASDAQ:HBIO)Earnings History by Quarter for Harvard Bioscience (NASDAQ:HBIO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/9/2017 | Q4 2016 | $0.04 | $0.01 | $26.90 million | $26.42 million | View | Listen | |
| 10/27/2016 | Q3 | $0.01 | $0.01 | $26.00 million | $25.01 million | View | Listen | |
| 7/28/2016 | Q2 | $0.03 | $0.03 | $26.60 million | $26.10 million | View | Listen | |
| 5/12/2016 | Q1 | $0.02 | $0.05 | $26.00 million | $27.00 million | View | Listen | |
| 4/29/2016 | Q4 | $0.03 | $0.03 | | $28.37 million | View | N/A | |
| 10/29/2015 | Q315 | $0.05 | $0.03 | $27.01 million | $25.70 million | View | Listen | |
| 7/30/2015 | Q215 | $0.04 | $0.05 | $26.60 million | $28.80 million | View | Listen | |
| 4/30/2015 | Q414 | $0.05 | $0.01 | $27.15 million | $25.80 million | View | Listen | |
| 2/26/2015 | Q314 | $0.09 | $0.08 | $29.30 million | $30.40 million | View | N/A | |
| 10/30/2014 | Q214 | $0.06 | $0.05 | $25.46 million | $25.40 million | View | N/A | |
| 7/31/2014 | Q2 | $0.05 | $0.05 | $26.00 million | $26.96 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.02) | $0.05 | $28.20 million | $27.90 million | View | N/A | |
| 10/31/2013 | Q313 | $0.01 | $0.05 | $26.10 million | $25.10 million | View | N/A | |
| 5/2/2013 | Q1 2013 | | $0.08 | $28.30 million | $26.10 million | View | N/A | |
| 11/1/2012 | Q312 | | $0.08 | $26.40 million | $26.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Harvard Bioscience (NASDAQ:HBIO)Current Year EPS Consensus Estimate: $0.15 EPS
Next Year EPS Consensus Estimate: $0.19 EPS
Dividend History for Harvard Bioscience (NASDAQ:HBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Harvard Bioscience (NASDAQ:HBIO)Insider Ownership Percentage: 8.80%
Institutional Ownership Percentage: 63.61%
Insider Trades by Quarter for Harvard Bioscience (NASDAQ:HBIO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/24/2017 | Earl R. Lewis | Director | Buy | 10,000 | $2.38 | $23,800.00 | |
| 2/7/2017 | David Green | Director | Sell | 3,239 | $3.25 | $10,526.75 | |
| 2/6/2017 | David Green | Director | Sell | 1,288 | $3.25 | $4,186.00 | |
| 12/6/2016 | Earl R. Lewis | Director | Sell | 23,088 | $2.42 | $55,872.96 | |
| 11/3/2016 | Jeffrey Duchemin | CEO | Buy | 15,000 | $2.42 | $36,300.00 | |
| 11/3/2016 | Robert E. Gagnon | CFO | Buy | 25,000 | $2.34 | $58,500.00 | |
| 12/10/2015 | Jeffrey Duchemin | CEO | Buy | 10,000 | $3.37 | $33,700.00 | |
| 12/3/2015 | George Uveges | Director | Buy | 3,000 | $3.32 | $9,960.00 | |
| 11/9/2015 | Robert E Gagnon | CFO | Buy | 3,000 | $3.08 | $9,240.00 | |
| 9/2/2015 | Jeffrey Duchemin | CEO | Buy | 2,000 | $4.41 | $8,820.00 | |
| 9/1/2015 | John F Kennedy | Director | Buy | 2,000 | $4.33 | $8,660.00 | |
| 7/17/2015 | David Green | Director | Sell | 17,103 | $5.26 | $89,961.78 | |
| 7/14/2015 | David Green | Director | Sell | 51,597 | $5.28 | $272,432.16 | |
| 4/23/2015 | David Green | Director | Sell | 118,500 | $6.03 | $714,555.00 | |
| 4/22/2015 | David Green | Director | Sell | 123,997 | $6.23 | $772,501.31 | |
| 4/17/2015 | David Green | Director | Sell | 42,503 | $6.55 | $278,394.65 | |
| 4/14/2015 | David Green | Director | Sell | 80,168 | $6.61 | $529,910.48 | |
| 2/9/2015 | David Green | Director | Sell | 48,712 | $5.25 | $255,738.00 | |
| 12/30/2014 | David Green | Director | Sell | 16,173 | $5.25 | $84,908.25 | |
| 12/29/2014 | David Green | Director | Sell | 100,167 | $5.25 | $525,876.75 | |
| 12/22/2014 | David Green | Director | Sell | 80,202 | $5.02 | $402,614.04 | |
| 11/19/2014 | David Green | Director | Sell | 10,000 | $4.95 | $49,500.00 | |
| 10/31/2014 | David Green | Director | Sell | 117,654 | $4.97 | $584,740.38 | |
| 6/16/2014 | Robert E Gagnon | CFO | Buy | 5,000 | $3.86 | $19,300.00 | |
| 5/29/2014 | Neal J Harte | Director | Sell | 12,317 | $3.82 | $47,050.94 | |
| 4/9/2014 | David Green | Director | Sell | 27,540 | $4.47 | $123,103.80 | |
| 4/8/2014 | David Green | Director | Sell | 66,090 | $4.48 | $296,083.20 | |
| 4/3/2014 | David Green | Director | Sell | 63,501 | $4.63 | $294,009.63 | |
| 8/27/2013 | Chane Graziano | Major Shareholder | Buy | 60,000 | $5.00 | $300,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Harvard Bioscience (NASDAQ:HBIO)
Latest Headlines for Harvard Bioscience (NASDAQ:HBIO)
| Source: |
|
| Date | Headline |
|---|
 | Harvard Bioscience, Inc. (HBIO) Director Earl R. Lewis Buys 10,000 Shares
www.americanbankingnews.com - May 25 at 8:28 PM |
 | ETFs with exposure to Harvard Bioscience, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 6:12 PM |
| Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 12:48 PM |
| Harvard Bioscience (HBIO) Earns Daily News Sentiment Rating of 0.57
www.americanbankingnews.com - May 3 at 10:30 AM |
| Harvard Bioscience (HBIO) Earning Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 30 at 10:51 AM |
| Harvard Bioscience, Inc. (HBIO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 29 at 1:13 AM |
| Edited Transcript of HBIO earnings conference call or presentation 27-Apr-17 8:30pm GMT
finance.yahoo.com - April 28 at 6:36 PM |
 | Harvard Bioscience reports 1Q loss
marketbeat.com - April 27 at 5:45 PM |
| Investor Network: Harvard Bioscience, Inc. to Host Earnings Call
finance.yahoo.com - April 27 at 3:33 PM |
| Somewhat Positive Media Coverage Very Likely to Impact Harvard Bioscience (HBIO) Share Price
www.americanbankingnews.com - April 26 at 9:24 PM |
| Harvard Bioscience Schedules First Quarter 2017 Conference Call for April 27 at 4:30 PM ET
finance.yahoo.com - April 19 at 8:43 PM |
| Harvard Bioscience (HBIO) Earning Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 13 at 11:16 AM |
| ETFs with exposure to Harvard Bioscience, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:30 PM |
| HARVARD BIOSCIENCE INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 17 at 5:51 PM |
 | Harvard Bioscience's (HBIO) CEO Jeffrey Duchemin on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 10 at 10:17 AM |
| Edited Transcript of HBIO earnings conference call or presentation 9-Mar-17 9:30pm GMT
finance.yahoo.com - March 10 at 10:17 AM |
| Q4 2016 Harvard Bioscience Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 9 at 6:01 PM |
 | Harvard Bioscience Reports Fourth Quarter and Year-End 2016 Results and 2017 Financial Guidance
us.rd.yahoo.com - March 9 at 6:01 PM |
| Harvard Bioscience, Inc. (HBIO) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 8 at 9:19 AM |
| Harvard Bioscience Schedules Fourth Quarter 2016 Conference Call for March 9 at 4:30 PM ET
finance.yahoo.com - February 23 at 5:37 PM |
| Harvard Bioscience, Inc. (HBIO) Presents At Singular Research "Uncovered Values & Special Situation Web Call"
seekingalpha.com - December 20 at 10:54 AM |
| Coverage initiated on Harvard Biosci by Singular Research
finance.yahoo.com - November 17 at 4:54 PM |
| HARVARD BIOSCIENCE INC Financials
finance.yahoo.com - November 10 at 4:46 PM |
| Edited Transcript of HBIO earnings conference call or presentation 27-Oct-16 8:30pm GMT
finance.yahoo.com - October 29 at 8:17 AM |
| Harvard Bioscience Inc Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - October 27 at 5:26 PM |
| Q3 2016 Harvard Bioscience Inc Earnings Release - After Market Close
biz.yahoo.com - October 27 at 10:07 AM |
| Harvard Bioscience (HBIO): Moving Average Crossover Alert
finance.yahoo.com - August 29 at 5:16 PM |
 | EXCLUSIVE: UW president lays out vision for Global Innovation Exchange
www.bizjournals.com - August 17 at 5:36 PM |
| 7:30 am Harvard Bioscience reports Q2; guides FY16
finance.yahoo.com - July 28 at 7:30 AM |
| Harvard Bioscience Schedules Second Quarter 2016 Conference Call for July 28 at 8:30 AM ET
finance.yahoo.com - July 18 at 4:30 PM |
| HARVARD BIOSCIENCE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - June 27 at 4:16 PM |
| HARVARD BIOSCIENCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
biz.yahoo.com - May 27 at 4:11 PM |
| Edited Transcript of HBIO earnings conference call or presentation 12-May-16 12:30pm GMT
finance.yahoo.com - May 12 at 10:50 AM |
| Q4 2015 and Q1 2016 Harvard Bioscience Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - May 12 at 8:30 AM |
| Q1 2016 Harvard Bioscience Inc Earnings Release - Before Market Open
biz.yahoo.com - May 12 at 7:07 AM |
| HARVARD BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
biz.yahoo.com - May 12 at 6:24 AM |
| Harvard Bioscience Regains Compliance with NASDAQ’s Continued Listing Requirements
finance.yahoo.com - May 4 at 4:15 PM |
 | Harvard Bioscience Reports Fourth Quarter And Year-End 2015 Results, Preliminary First Quarter 2016 Revenues And 2016 Financial Guidance
www.thestreet.com - April 29 at 5:42 PM |
| Harvard Bioscience to delay 10-K filing, reports Preliminary Q4 revenue
seekingalpha.com - March 28 at 6:55 PM |
Harvard Bioscience (HBIO) Chart for Thursday, May, 25, 2017
